Regenerative Medicine and Stem Cells Technologies

PRPs can be used in the management of tendinopathy if we improve our understanding of pathophysiology and to integrate molecular knowledge about PRP participation in healing mechanisms.

China wants to go big on biotech and already is marching into experimental gene therapy.

Many of the genes involved in the natural repair of the injured spinal cord of the lamprey are also active in the repair of the peripheral nervous system in mammals, according to a study by a collaborative group of scientists at the Marine Biological Laboratory and other institutions.

In March 2016, it was revealed that a stem-cell therapy had given 12 Chinese infants suffering from cataracts the ability to see clearly (H. Lin et al. Nature 531, 323–328; 2016).

There are no prizes for coming second, at least no Nobel prizes which is why everyone’s eyes will be on Stockholm next week when the greatest accolades in science will be announced.

The National Cancer Institute has awarded Cleveland Clinic a collaborative $2.6 million grant to create models of colorectal cancer that will enhance understanding of how the disease develops and spreads, according to a news release.

Stem cell researchers at Emory University School of Medicine have made an advance toward having a long-lasting "repair caulk" for blood vessels. The research could form the basis of a treatment for peripheral artery disease, derived from a patients own cells. Their results were recently published in the journal Circulation.

Both, blood and bone of human beings have the potential to regenerate. This capacity is owed to multipotent stem cells that can differentiate into various cell types: Hematopoietic stem cells (HSCs) are precursors of all cell types of the blood; mesenchymal stem cells (MSCs) are precursor cells of the connective tissue and may differentiate to bone, cartilage, and muscle cells.

In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therapy.

A type of mouse widely used to assess how the human immune system responds to transplanted stem cells does not reflect what is likely to occur in patients, according to a study by researchers at the Stanford University School of Medicine.